Read our latest updates & insights

CA approval for Celltrion/Hospira’s infliximab biosimilar products to be marketed as Remsima® and Inflectra®.

EMA welcomes Apotex’s biosimilar Filgrastim rendition, Grastofil®, throughout Europe.

Hospira/Celltrion’s infliximab biosimilar products approved in EU (Remsima® and Inflectra®).

Stada and Gedeon Richter announce collaboration deals to develop and sell biosimilars rituximab and trastuzumab.

European Commission (EC) withdraws EU marketing authorisation following Filgrastim Ratiopharm® MAH’s voluntary withdrawal.

A Biosimilar product of Filgrastim was approved by the European Commission and marketed across several European countries under the name of Nivestim®.

Tanvex submits New Drug Submission to Health Canada for biosimilar filgrastim.

Sandoz’ EP2006 was approved by EMA for marketing in the European Union (EU) under the trade name Zarzio® as a biosimilar product to EU-approved Neupogen®.

Hexal releases European biosimilar version of filgrastim, Filgrastim Hexal®.

In accordance to the 2014 European Public Assessment Report (EPAR) Certified by EMA, Ratiopharm marketed a biological medicine in late 2008 known as Ratiograstin®. This medicine is a biosimilar to the previously pattened EU authorised Filgrastim (Neupogen®).